Cristina Saura

Cristina Saura

UNVERIFIED PROFILE

Are you Cristina Saura?   Register this Author

Register author
Cristina Saura

Cristina Saura

Publications by authors named "Cristina Saura"

Are you Cristina Saura?   Register this Author

37Publications

977Reads

15Profile Views

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Oncologist 2019 May 1;24(5):603-611. Epub 2019 Feb 1.

Department of Medical Oncology and Hematology, Hospital Clínico Universitario, University of Valencia-INCLIVA Health Research Institute, CIBERONC, Valencia, Spain.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2018-0228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516119PMC
May 2019

From Standard of Care to the Neoadjuvant Model as an Innovative Platform for Exploring Promising Combinations in Breast Cancer.

Authors:
Cristina Saura

Breast Care (Basel) 2018 Aug 24;13(4):236-237. Epub 2018 Aug 24.

Breast Cancer Unit, Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167678PMC
August 2018

HER2-positive breast cancer: Current and new therapeutic strategies.

Breast 2018 Jun 6;39:80-88. Epub 2018 Apr 6.

Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776183005
Publisher Site
http://dx.doi.org/10.1016/j.breast.2018.03.006DOI Listing
June 2018

Menopause status is associated with circadian- and sleep-related alterations.

Menopause 2016 06;23(6):682-90

1Department of Physiology, Faculty of Biology, University of Murcia, Murcia, Spain 2Universidad Autónoma de Chile, Santiago de Chile, Chile 3IMIB-Arrixaca, Murcia, Spain 4Neumology Service of Hospital Virgen de Arrixaca, Murcia, Spain 5Instrumentation Service Psychological, University of Murcia, Murcia, Spain.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/GME.0000000000000612DOI Listing
June 2016

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

J Clin Oncol 2014 Nov 6;32(32):3626-33. Epub 2014 Oct 6.

Cristina Saura and Javier Cortés, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Jose A. Garcia-Saenz, Hospital Clinico San Carlos; Miguel Martin, Hospital Gregorio Maranon, Universidad Complutense, Madrid, Spain; Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Wael Harb, Horizon Medical Group, Lafayette, IN; Rebecca Moroose, University of Florida Health Cancer Center, Orlando, FL; Timothy Pluard, Washington University School of Medicine, St Louis, MO; Corinne Kiger, Pfizer Global Research and Development, Paris; Caroline Germa, Novartis Pharma, Rueil-Malmaison, France; Kongming Wang, Pfizer, Pearl River; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; and Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.3809DOI Listing
November 2014

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.

Clin Cancer Res 2014 Apr 27;20(7):1935-45. Epub 2014 Jan 27.

Authors' Affiliations: Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Catalan Institute of Oncology, Barcelona, Spain; Sarah Cannon Research Institute, Nashville, Tennessee; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharmaceuticals, Florham Park, New Jersy; C.H.U. Sart-Tilman, Liege; Oncologisch Centrum AZ-St. Augustinus Oncology, Antwerp, Belgium; Novartis Pharma AG, Basel, Switzerland; Novartis Oncology, Paris, France; Memorial Sloan-Kettering Cancer Centre, New York, New York; Highlands Oncology Group, Fayetteville, Arkansas; and Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1070DOI Listing
April 2014

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res 2013 Dec 18;19(24):6976-86. Epub 2013 Oct 18.

Authors' Affiliations: Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc., DNA Way, South San Francisco, California; Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d'Hebron Institute of Oncology, Barcelona; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0978DOI Listing
December 2013

Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes.

Breast 2013 Aug 30;22(4):515-9. Epub 2012 Oct 30.

Vall d'Hebron Breast Cancer Center, Service of Gynecology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2012.10.005DOI Listing
August 2013

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.

Breast 2013 Feb 6;22(1):19-23. Epub 2012 Nov 6.

Breast Cancer Center, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2012.10.009DOI Listing
February 2013

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Mol Cancer Ther 2012 Sep 21;11(9):2062-71. Epub 2012 Jun 21.

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/11/9/2062.full.pdf
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0290DOI Listing
September 2012

Molecular prescreening to select patient population in early clinical trials.

Nat Rev Clin Oncol 2012 04 3;9(6):359-66. Epub 2012 Apr 3.

Medical Oncology Department, Vall d'Hebrón University Hospital, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.48DOI Listing
April 2012

HER2 and hormone receptor-positive breast cancer--blocking the right target.

Nat Rev Clin Oncol 2011 05 14;8(5):307-11. Epub 2010 Dec 14.

Vall d'Hebron University Hospital, Oncology Department, Breast Cancer Unit, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2010.185
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2010.185DOI Listing
May 2011

A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer.

Breast Cancer Res Treat 2010 May 1;121(1):221-5. Epub 2009 Aug 1.

Oncogenetics Laboratory, University Hospital Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-009-0494-y
Publisher Site
http://dx.doi.org/10.1007/s10549-009-0494-yDOI Listing
May 2010

Novel targets for anticancer treatment development in colorectal cancer.

Clin Colorectal Cancer 2006 Nov;6(4):265-72

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2006.n.045DOI Listing
November 2006